PKI - Danaher earnings weigh on other life sciences tools services companies
- Danaher ( NYSE: DHR ), which reported slowing topline growth in its Q4 2022 financial results earlier Tuesday, is impacting other life sciences tools and services providers.
- The biggest decliner among peers is Repligen ( NASDAQ: RGEN ), off ~4.3% . Others include Thermo Fisher Scientific ( NYSE: TMO ), down 4% , and PerkinElmer ( NYSE: PKI ), down 3.8% .
- Danaher reported only 3% year-over-year revenue growth in the quarter.
- Read why Seeking Alpha contributor Harold Goldmeier, who has a buy rating on Thermo Fisher ( TMO ), says the company is poised for growth .
For further details see:
Danaher earnings weigh on other life sciences tools, services companies